| Genzyme Belgium | Genzyme Corporate | Search | Contact us | |||||||||
![]() |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
MPS I – Auditory System Moderate to severe hearing loss, which correlates with the severity of somatic disease, can occur in patients with MPS I. Hearing loss may be sensorineural or conductive, but is typically mixed[1, 2]. Hearing impairment is most common in the high frequency range and thus can lead to significant difficulties in social interaction. References 1. Clarke, L.A. (1997) Clinical diagnosis of lysosomal storage diseases. In: Organelle Diseases. Clinical Features, Diagnosis, Pathogenesis and Management. Applegarth, D.A., Dimmick, J.E., and Hall, J.G. (eds.). Chapman and Hall Medical, London, pp. 37. 2. Neufeld, E.F., and Muenzer, J. (2001) The mucopolysaccharidoses. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., Childs, B., Kinzler, K.W., and Vogelstein, B. (eds.). 8th edition, Vol. III. McGraw-Hill, Medical Publishing Division, pp. 3421. |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Terms and Conditions of Use | Privacy Policy | © 2012 Genzyme Corporation, a Sanofi Company. All rights reserved. | ||